FTRE
Fortrea Holdings Inc.
NASDAQ · Healthcare · Biotechnology · US
$19.93
−1.73%Sep 10, 2026, 21:08 UTC
Fortrea granted inducement awards of restricted stock units and performance share units to five newly hired employees on September 10, 2026.
Source:Sep 10, 2026, 11:02 UTC
Fortrea Holdings Inc. appointed Jason Knoblauch as Chief Financial Officer effective September 9, 2026, with David Smith serving as Interim Chief Financial Officer.
Sep 2, 2026, 11:00 UTC
Fortrea agreed to acquire the clinical pharmacology unit and bioanalytical laboratory operations from Worldwide Clinical Trials, adding dedicated bioanalytical capabilities and expanded capacity to Fortrea's early clinical development network.
Jul 29, 2026, 10:30 UTC
Fortrea reports its second quarter 2026 financial results and raises full-year guidance.
Jul 29, 2026, 00:00 UTC
Fortrea Holdings Inc. appointed David Smith as Interim Chief Financial Officer and principal financial officer, effective July 27, 2026.
Jun 26, 2026, 11:00 UTC
Fortrea appointed Jason Knoblauch as its new Chief Financial Officer, succeeding Jill McConnell.
Source: